Literature DB >> 27307567

Repair of a Mutation Disrupting the Guinea Pig Cytomegalovirus Pentameric Complex Acquired during Fibroblast Passage Restores Pathogenesis in Immune-Suppressed Guinea Pigs and in the Context of Congenital Infection.

Michael A McVoy1, Jian Ben Wang1, Dirk P Dittmer2, Craig J Bierle3, Elizabeth C Swanson3, Claudia Fernández-Alarcón3, Nelmary Hernandez-Alvarado1, Jason C Zabeli3, Mark R Schleiss4.   

Abstract

UNLABELLED: Guinea pig cytomegalovirus (GPCMV) provides a valuable model for congenital cytomegalovirus transmission. Salivary gland (SG)-passaged stocks of GPCMV are pathogenic, while tissue culture (TC) passage in fibroblasts results in attenuation. Nonpathogenic TC-derived virus N13R10 (cloned as a bacterial artificial chromosome [BAC]) has a 4-bp deletion that disrupts GP129, which encodes a subunit of the GPCMV pentameric complex (PC) believed to govern viral entry into select cell types, and GP130, an overlapping open reading frame (ORF) of unknown function. To determine if this deletion contributes to attenuation of N13R10, markerless gene transfer in Escherichia coli was used to construct virus r129, a variant of N13R10 in which the 4-bp deletion is repaired. Virions from r129 were found to contain GP129 as well as two other PC subunit proteins, GP131 and GP133, whereas these three PC subunits were absent from N13R10 virions. Replication of r129 in fibroblasts appeared unaltered compared to that of N13R10. However, following experimental challenge of immunocompromised guinea pigs, r129 induced significant weight loss, longer duration of viremia, and dramatically higher (up to 1.5 × 10(6)-fold) viral loads in blood and end organs compared to N13R10. In pregnant guinea pigs, challenge with doses of r129 virus of ≥5 × 10(6) PFU resulted in levels of maternal viremia, congenital transmission, pup viral loads, intrauterine growth restriction, and pup mortality comparable to that induced by pathogenic SG virus, although higher doses of r129 were required. These results suggest that the GP129-GP130 mutation is a significant contributor to attenuation of N13R10, likely by abrogating expression of a functional PC. IMPORTANCE: Tissue culture adaptation of cytomegaloviruses rapidly selects for mutations, deletions, and rearrangements in the genome, particularly for viruses passaged in fibroblast cells. Some of these mutations are focused in the region of the genome encoding components of the pentameric complex (PC), in particular homologs of human cytomegalovirus (HCMV) proteins UL128, UL130, and UL131A. These mutations can attenuate the course of infection when the virus is reintroduced into animals for vaccine and pathogenesis studies. This study demonstrates that a deletion that arose during the process of tissue culture passage can be repaired, with subsequent restoration of pathogenicity, using BAC-based mutagenesis. Restoration of pathogenicity by repair of a frameshift mutation in GPCMV gene GP129 using this approach provides a valuable genetic platform for future studies using the guinea pig model of congenital CMV infection.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27307567      PMCID: PMC4988165          DOI: 10.1128/JVI.00320-16

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  53 in total

1.  Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.

Authors:  Fernando J Bravo; David I Bernstein; James R Beadle; Karl Y Hostetler; Rhonda D Cardin
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

2.  Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin.

Authors:  Ashley E Fouts; Pamela Chan; Jean-Philippe Stephan; Richard Vandlen; Becket Feierbach
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

3.  Human cytomegalovirus UL130 protein promotes endothelial cell infection through a producer cell modification of the virion.

Authors:  Marco Patrone; Massimiliano Secchi; Loretta Fiorina; Mariagrazia Ierardi; Gabriele Milanesi; Andrea Gallina
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

4.  Protein pUL128 of human cytomegalovirus is necessary for monocyte infection and blocking of migration.

Authors:  Sarah Straschewski; Marco Patrone; Paul Walther; Andrea Gallina; Thomas Mertens; Giada Frascaroli
Journal:  J Virol       Date:  2011-03-02       Impact factor: 5.103

5.  Glycoprotein B (gB) vaccines adjuvanted with AS01 or AS02 protect female guinea pigs against cytomegalovirus (CMV) viremia and offspring mortality in a CMV-challenge model.

Authors:  Mark R Schleiss; K Yeon Choi; Jodi Anderson; Janine Gessner Mash; Martine Wettendorff; Sally Mossman; Marc Van Damme
Journal:  Vaccine       Date:  2013-07-16       Impact factor: 3.641

6.  Antibodies against neutralization epitopes of human cytomegalovirus gH/gL/pUL128-130-131 complex and virus spreading may correlate with virus control in vivo.

Authors:  Daniele Lilleri; Anna Kabanova; Antonio Lanzavecchia; Giuseppe Gerna
Journal:  J Clin Immunol       Date:  2012-07-27       Impact factor: 8.317

7.  Virulence and attenuation of murine cytomegalovirus.

Authors:  J E Osborn; D L Walker
Journal:  Infect Immun       Date:  1971-02       Impact factor: 3.441

8.  Characterization of the guinea pig CMV gH/gL/GP129/GP131/GP133 complex in infection and spread.

Authors:  Marcy Auerbach; Donghong Yan; Ashley Fouts; Min Xu; Alberto Estevez; Cary D Austin; Fernando Bazan; Becket Feierbach
Journal:  Virology       Date:  2013-04-04       Impact factor: 3.616

9.  HCMV spread and cell tropism are determined by distinct virus populations.

Authors:  Laura Scrivano; Christian Sinzger; Hans Nitschko; Ulrich H Koszinowski; Barbara Adler
Journal:  PLoS Pathog       Date:  2011-01-13       Impact factor: 6.823

10.  A neutralizing anti-gH/gL monoclonal antibody is protective in the guinea pig model of congenital CMV infection.

Authors:  Marcy R Auerbach; Donghong Yan; Rajesh Vij; Jo-Anne Hongo; Gerald Nakamura; Jean-Michel Vernes; Y Gloria Meng; Samantha Lein; Pamela Chan; Jed Ross; Richard Carano; Rong Deng; Nicholas Lewin-Koh; Min Xu; Becket Feierbach
Journal:  PLoS Pathog       Date:  2014-04-10       Impact factor: 6.823

View more
  11 in total

Review 1.  Prospects of a vaccine for the prevention of congenital cytomegalovirus disease.

Authors:  Bodo Plachter
Journal:  Med Microbiol Immunol       Date:  2016-08-12       Impact factor: 3.402

Review 2.  Chemokines encoded by herpesviruses.

Authors:  Sergio M Pontejo; Philip M Murphy
Journal:  J Leukoc Biol       Date:  2017-08-28       Impact factor: 4.962

Review 3.  Animal Models of Congenital Cytomegalovirus Transmission: Implications for Vaccine Development.

Authors:  Hunter K Roark; Jennifer A Jenks; Sallie R Permar; Mark R Schleiss
Journal:  J Infect Dis       Date:  2020-03-05       Impact factor: 5.226

4.  A Guinea pig cytomegalovirus resistant to the DNA maturation inhibitor BDCRB.

Authors:  Amine Ourahmane; Anne Sauer; Daniel E Nixon; Christine Murphy; Melissa Mondello; Erin Douglass Chiu; Stephanie Siegmund; Jian Ben Wang; Michael A McVoy
Journal:  Antiviral Res       Date:  2018-04-09       Impact factor: 5.970

Review 5.  A fifty-year odyssey: prospects for a cytomegalovirus vaccine in transplant and congenital infection.

Authors:  Don Jeffrey Diamond; Corinna La Rosa; Flavia Chiuppesi; Heidi Contreras; Sanjeet Dadwal; Felix Wussow; Supriya Bautista; Ryotaro Nakamura; John A Zaia
Journal:  Expert Rev Vaccines       Date:  2018-10-03       Impact factor: 5.217

6.  In vitro and in vivo characterization of a recombinant rhesus cytomegalovirus containing a complete genome.

Authors:  Husam Taher; Eisa Mahyari; Craig Kreklywich; Luke S Uebelhoer; Matthew R McArdle; Matilda J Moström; Amruta Bhusari; Michael Nekorchuk; Xiaofei E; Travis Whitmer; Elizabeth A Scheef; Lesli M Sprehe; Dawn L Roberts; Colette M Hughes; Kerianne A Jackson; Andrea N Selseth; Abigail B Ventura; Hillary C Cleveland-Rubeor; Yujuan Yue; Kimberli A Schmidt; Jason Shao; Paul T Edlefsen; Jeremy Smedley; Timothy F Kowalik; Richard J Stanton; Michael K Axthelm; Jacob D Estes; Scott G Hansen; Amitinder Kaur; Peter A Barry; Benjamin N Bimber; Louis J Picker; Daniel N Streblow; Klaus Früh; Daniel Malouli
Journal:  PLoS Pathog       Date:  2020-11-24       Impact factor: 7.464

Review 7.  Pathogen at the Gates: Human Cytomegalovirus Entry and Cell Tropism.

Authors:  Christopher C Nguyen; Jeremy P Kamil
Journal:  Viruses       Date:  2018-12-11       Impact factor: 5.048

Review 8.  Promising Cytomegalovirus-Based Vaccine Vector Induces Robust CD8+ T-Cell Response.

Authors:  Jian Liu; Dabbu Kumar Jaijyan; Qiyi Tang; Hua Zhu
Journal:  Int J Mol Sci       Date:  2019-09-10       Impact factor: 5.923

9.  MVA-Vectored Pentameric Complex (PC) and gB Vaccines Improve Pregnancy Outcome after Guinea Pig CMV Challenge, but Only gB Vaccine Reduces Vertical Transmission.

Authors:  Heidi Contreras; Felix Wussow; Claudia Fernández-Alarcón; Craig Bierle; Jenny Nguyen; Don J Diamond; Mark R Schleiss
Journal:  Vaccines (Basel)       Date:  2019-11-14

10.  Inclusion of the Guinea Pig Cytomegalovirus Pentameric Complex in a Live Virus Vaccine Aids Efficacy against Congenital Infection but Is Not Essential for Improving Maternal and Neonatal Outcomes.

Authors:  Mark R Schleiss; Claudia Fernández-Alarcón; Nelmary Hernandez-Alvarado; Jian Ben Wang; Adam P Geballe; Michael A McVoy
Journal:  Viruses       Date:  2021-11-26       Impact factor: 5.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.